Capricor Free Cash Flow Per Share vs Free Cash Flow Yield Analysis

CAPR Stock

USD 19.01 0.03 0.16%

Capricor Therapeutics financial indicator trend analysis is way more than just evaluating Capricor Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Capricor Therapeutics is a good investment. Please check the relationship between Capricor Therapeutics Free Cash Flow Per Share and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Free Cash Flow Per Share vs Free Cash Flow Yield

Free Cash Flow Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Capricor Therapeutics Free Cash Flow Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Capricor Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield is -0.03. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Capricor Therapeutics, assuming nothing else is changed. The correlation between historical values of Capricor Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Capricor Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Free Cash Flow Per Share i.e., Capricor Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Capricor Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Capricor Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.At this time, Capricor Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 11/30/2024, Issuance Of Capital Stock is likely to grow to about 9.8 M, while Enterprise Value Over EBITDA is likely to drop (5.41).

Capricor Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Total Current Assets	Other Current Liab	Short Long Term Debt Total	Short Term Debt	Property Plant And Equipment Net	Other Current Assets	Property Plant And Equipment Gross	Intangible Assets	Net Tangible Assets	Other Assets
Total Assets		0.88	0.78	-0.93	0.97	0.92	0.07	0.08	0.97	0.93	0.83	0.11	-0.59	0.53	0.98	0.74	1.0	0.04	-0.1	-0.43	0.94	0.69	0.93	-0.13	0.56	0.91
Total Current Liabilities	0.88		0.47	-0.82	0.92	0.93	-0.04	0.09	0.82	0.8	0.92	0.12	-0.17	0.09	0.79	0.88	0.86	-0.35	-0.12	-0.28	0.93	0.38	0.94	-0.13	0.15	0.82
Total Stockholder Equity	0.78	0.47		-0.78	0.64	0.62	0.21	0.14	0.85	0.85	0.3	0.16	-0.89	0.71	0.82	0.49	0.79	0.45	-0.39	-0.62	0.67	0.85	0.66	-0.05	0.92	0.74
Retained Earnings	-0.93	-0.82	-0.78		-0.87	-0.86	-0.12	-0.3	-0.94	-0.99	-0.72	-0.33	0.52	-0.4	-0.91	-0.72	-0.92	-0.13	0.18	0.44	-0.92	-0.71	-0.91	-0.03	-0.58	-0.91
Accounts Payable	0.97	0.92	0.64	-0.87		0.93	-0.02	0.08	0.9	0.87	0.91	0.11	-0.45	0.44	0.92	0.79	0.96	-0.08	0.05	-0.29	0.92	0.55	0.92	-0.13	0.39	0.87
Non Current Assets Total	0.92	0.93	0.62	-0.86	0.93		0.1	0.06	0.91	0.85	0.86	0.09	-0.35	0.26	0.86	0.78	0.9	-0.14	-0.22	-0.4	0.97	0.54	0.97	-0.14	0.38	0.93
Non Currrent Assets Other	0.07	-0.04	0.21	-0.12	-0.02	0.1		0.01	0.01	0.14	-0.09	0.01	-0.19	0.1	0.09	0.01	0.06	0.04	-0.18	-0.37	0.01	0.13	0.01	-0.06	0.23	0.12
Common Stock Total Equity	0.08	0.09	0.14	-0.3	0.08	0.06	0.01		0.13	0.27	0.0	1.0	-0.12	0.03	0.09	0.1	0.09	-0.09	-0.01	0.22	0.14	0.03	0.14	0.17	0.14	0.07
Common Stock Shares Outstanding	0.97	0.82	0.85	-0.94	0.9	0.91	0.01	0.13		0.95	0.72	0.16	-0.63	0.5	0.96	0.7	0.96	0.13	-0.26	-0.48	0.95	0.77	0.94	-0.11	0.67	0.93
Other Stockholder Equity	0.93	0.8	0.85	-0.99	0.87	0.85	0.14	0.27	0.95		0.67	0.29	-0.6	0.46	0.92	0.72	0.93	0.19	-0.23	-0.49	0.91	0.74	0.9	0.01	0.65	0.91
Total Liab	0.83	0.92	0.3	-0.72	0.91	0.86	-0.09	0.0	0.72	0.67		0.03	-0.11	0.18	0.77	0.7	0.82	-0.34	0.19	-0.11	0.83	0.3	0.83	-0.16	0.04	0.73
Common Stock	0.11	0.12	0.16	-0.33	0.11	0.09	0.01	1.0	0.16	0.29	0.03		-0.13	0.04	0.11	0.13	0.11	-0.1	-0.02	0.21	0.17	0.04	0.17	0.16	0.14	0.1
Net Debt	-0.59	-0.17	-0.89	0.52	-0.45	-0.35	-0.19	-0.12	-0.63	-0.6	-0.11	-0.13		-0.92	-0.69	-0.17	-0.62	-0.52	0.18	0.47	-0.39	-0.76	-0.37	0.15	-0.93	-0.46
Cash	0.53	0.09	0.71	-0.4	0.44	0.26	0.1	0.03	0.5	0.46	0.18	0.04	-0.92		0.64	0.04	0.56	0.55	0.16	-0.29	0.27	0.67	0.25	-0.15	0.8	0.36
Cash And Short Term Investments	0.98	0.79	0.82	-0.91	0.92	0.86	0.09	0.09	0.96	0.92	0.77	0.11	-0.69	0.64		0.61	0.99	0.14	-0.07	-0.46	0.88	0.76	0.87	-0.14	0.66	0.87
Net Receivables	0.74	0.88	0.49	-0.72	0.79	0.78	0.01	0.1	0.7	0.72	0.7	0.13	-0.17	0.04	0.61		0.73	-0.29	-0.2	-0.26	0.79	0.28	0.82	-0.08	0.13	0.72
Total Current Assets	1.0	0.86	0.79	-0.92	0.96	0.9	0.06	0.09	0.96	0.93	0.82	0.11	-0.62	0.56	0.99	0.73		0.07	-0.08	-0.43	0.92	0.71	0.91	-0.13	0.58	0.89
Other Current Liab	0.04	-0.35	0.45	-0.13	-0.08	-0.14	0.04	-0.09	0.13	0.19	-0.34	-0.1	-0.52	0.55	0.14	-0.29	0.07		-0.11	-0.34	-0.09	0.55	-0.12	0.44	0.64	0.15
Short Long Term Debt Total	-0.1	-0.12	-0.39	0.18	0.05	-0.22	-0.18	-0.01	-0.26	-0.23	0.19	-0.02	0.18	0.16	-0.07	-0.2	-0.08	-0.11		0.64	-0.23	-0.3	-0.23	-0.12	-0.35	-0.27
Short Term Debt	-0.43	-0.28	-0.62	0.44	-0.29	-0.4	-0.37	0.22	-0.48	-0.49	-0.11	0.21	0.47	-0.29	-0.46	-0.26	-0.43	-0.34	0.64		-0.4	-0.66	-0.39	-0.25	-0.58	-0.54
Property Plant And Equipment Net	0.94	0.93	0.67	-0.92	0.92	0.97	0.01	0.14	0.95	0.91	0.83	0.17	-0.39	0.27	0.88	0.79	0.92	-0.09	-0.23	-0.4		0.62	1.0	-0.1	0.44	0.95
Other Current Assets	0.69	0.38	0.85	-0.71	0.55	0.54	0.13	0.03	0.77	0.74	0.3	0.04	-0.76	0.67	0.76	0.28	0.71	0.55	-0.3	-0.66	0.62		0.59	0.18	0.88	0.73
Property Plant And Equipment Gross	0.93	0.94	0.66	-0.91	0.92	0.97	0.01	0.14	0.94	0.9	0.83	0.17	-0.37	0.25	0.87	0.82	0.91	-0.12	-0.23	-0.39	1.0	0.59		-0.1	0.42	0.94
Intangible Assets	-0.13	-0.13	-0.05	-0.03	-0.13	-0.14	-0.06	0.17	-0.11	0.01	-0.16	0.16	0.15	-0.15	-0.14	-0.08	-0.13	0.44	-0.12	-0.25	-0.1	0.18	-0.1		-0.02	0.1
Net Tangible Assets	0.56	0.15	0.92	-0.58	0.39	0.38	0.23	0.14	0.67	0.65	0.04	0.14	-0.93	0.8	0.66	0.13	0.58	0.64	-0.35	-0.58	0.44	0.88	0.42	-0.02		0.55
Other Assets	0.91	0.82	0.74	-0.91	0.87	0.93	0.12	0.07	0.93	0.91	0.73	0.1	-0.46	0.36	0.87	0.72	0.89	0.15	-0.27	-0.54	0.95	0.73	0.94	0.1	0.55

Click cells to compare fundamentals

Capricor Therapeutics Account Relationship Matchups

Capricor Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.1M	34.6M	41.3M	50.1M	58.7M	61.7M
Total Current Liabilities	898.0K	3.0M	4.1M	23.6M	31.3M	32.8M
Total Stockholder Equity	6.8M	28.2M	31.4M	11.8M	22.6M	23.7M
Retained Earnings	(74.4M)	(88.0M)	(108.1M)	(137.1M)	(159.4M)	(151.4M)
Accounts Payable	898.0K	2.7M	3.7M	4.8M	6.2M	6.5M
Non Current Assets Total	1.2M	941.7K	4.9M	7.2M	7.9M	8.3M
Non Currrent Assets Other	779.0K	88.7K	275.7K	268.2K	308.4K	234.9K
Common Stock Total Equity	5.2K	20.6K	24.2K	25.2K	29.0K	20.1K
Common Stock Shares Outstanding	3.7M	15.6M	23.1M	24.6M	26.8M	28.1M
Liabilities And Stockholders Equity	11.1M	34.6M	41.3M	50.1M	58.7M	61.7M
Other Stockholder Equity	81.2M	116.2M	139.4M	148.7M	181.7M	190.8M
Total Liab	4.3M	6.4M	10.0M	38.3M	36.1M	37.9M
Common Stock	5.2K	20.6K	24.2K	25.2K	31.1K	20.7K
Net Debt	(523.1K)	(32.3M)	(32.0M)	(7.0M)	(12.5M)	(11.8M)
Cash	3.9M	32.7M	34.9M	9.6M	14.7M	8.4M
Cash And Short Term Investments	9.9M	32.7M	34.9M	41.4M	39.5M	41.5M
Net Receivables	88.0K	56K	391.8K	547.6K	10.4M	10.9M
Total Current Assets	9.9M	33.7M	36.4M	42.9M	50.9M	53.4M
Short Long Term Debt Total	3.4M	3.7M	3.8M	4.1M	2.2M	2.1M
Property Plant And Equipment Net	442.8K	850.8K	4.6M	6.9M	7.6M	8.0M
Other Current Assets	571.4K	1.0M	1.2M	919.9K	995.8K	572.0K
Property Plant And Equipment Gross	442.8K	850.8K	5.4M	8.1M	9.8M	10.3M
Accumulated Other Comprehensive Income	12.4K	(757.0)	0.0	105.2K	235.8K	247.6K
Intangible Assets	93.0K	49.8M	6.5M	2.2M	2.5M	2.4M
Net Tangible Assets	6.8M	28.2M	36.7M	11.8M	13.6M	7.6M
Other Assets	119.6K	88.7K	275.7K	268.2K	308.4K	323.8K
Retained Earnings Total Equity	(74.4M)	(88.0M)	(108.1M)	(137.1M)	(123.4M)	(117.2M)
Short Term Investments	8.0M	3.0M	6.0M	31.8M	24.8M	26.0M
Capital Surpluse	81.2M	116.2M	139.4M	148.7M	171.0M	179.6M
Inventory	285.8K	(659.4K)	(56K)	1.0	0.9	0.86
Property Plant Equipment	442.8K	850.8K	4.6M	4.6M	5.3M	5.5M

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Capricor Stock

0.7	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.91	EWTX	Edgewise Therapeutics	Pair Corr
0.76	BHC	Bausch Health Companies	Pair Corr

Moving against Capricor Stock

0.78	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.72	TAK	Takeda Pharmaceutical	Pair Corr
0.7	ELAN	Elanco Animal Health	Pair Corr
0.64	HLN	Haleon plc	Pair Corr
0.62	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.

The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC